Suspect Science Leads to Pause in Stem Cell Trial. Kaiser, J. 362(6414):513. ![Suspect Science Leads to Pause in Stem Cell Trial [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex [Excerpt] [...] In mid-October, Harvard University officials disclosed that they have called for the retraction of 31 papers [...] studying the potential of stem cells to repair the heart. And this week, federal officials paused a related clinical study, explaining that the pending retractions ” have raised concerns about the scientific foundations of this trial.” [...] Some critics of his work say studies like the now-halted trial should never have started, given long-standing questions about how – and whether – the cells Anversa studied might repair heart tissue. ” The problem is that if you don't know how something works, then you don't really have a road map of what to address to make it better,” says Deepak Srivastava, a pediatric cardiologist and president of the Gladstone Institutes in San Francisco, California. [...] Further concerns arose this month when Harvard and Brigham and Women's recommended that 31 papers from the Anversa lab be retracted because they ” included falsified and/or fabricated data.” [...] some researchers think the trial should be completed. ” There's plenty of reason to believe that there's still promise,” says cardiologist Christopher Granger of Duke University in Durham, North Carolina. Bolli [...] points to ” overwhelming evidence” from animal studies that c-kit+ cells somehow promote heart tissue growth. ” The controversy [...] does not really change the validity of using c-kit+ cells,” Bolli says. [...]
@article{kaiserSuspectScienceLeads2018,
title = {Suspect Science Leads to Pause in Stem Cell Trial},
author = {Kaiser, Jocelyn},
date = {2018-11},
journaltitle = {Science},
volume = {362},
pages = {513},
issn = {0036-8075},
doi = {10.1126/science.362.6414.513},
url = {https://doi.org/10.1126/science.362.6414.513},
abstract = {[Excerpt] [...] In mid-October, Harvard University officials disclosed that they have called for the retraction of 31 papers [...] studying the potential of stem cells to repair the heart. And this week, federal officials paused a related clinical study, explaining that the pending retractions ” have raised concerns about the scientific foundations of this trial.” [...] Some critics of his work say studies like the now-halted trial should never have started, given long-standing questions about how -- and whether -- the cells Anversa studied might repair heart tissue. ” The problem is that if you don't know how something works, then you don't really have a road map of what to address to make it better,” says Deepak Srivastava, a pediatric cardiologist and president of the Gladstone Institutes in San Francisco, California. [...] Further concerns arose this month when Harvard and Brigham and Women's recommended that 31 papers from the Anversa lab be retracted because they ” included falsified and/or fabricated data.” [...] some researchers think the trial should be completed. ” There's plenty of reason to believe that there's still promise,” says cardiologist Christopher Granger of Duke University in Durham, North Carolina. Bolli [...] points to ” overwhelming evidence” from animal studies that c-kit+ cells somehow promote heart tissue growth. ” The controversy [...] does not really change the validity of using c-kit+ cells,” Bolli says. [...]},
keywords = {*imported-from-citeulike-INRMM,~INRMM-MiD:c-14652919,epistemology,publication-bias,publish-or-perish,research-management,science-ethics,scientific-community-self-correction,scientific-misconduct},
number = {6414}
}
Downloads: 0
{"_id":"h8vnFyckEszogrD4C","bibbaseid":"kaiser-suspectscienceleadstopauseinstemcelltrial","authorIDs":[],"author_short":["Kaiser, J."],"bibdata":{"bibtype":"article","type":"article","title":"Suspect Science Leads to Pause in Stem Cell Trial","author":[{"propositions":[],"lastnames":["Kaiser"],"firstnames":["Jocelyn"],"suffixes":[]}],"date":"2018-11","journaltitle":"Science","volume":"362","pages":"513","issn":"0036-8075","doi":"10.1126/science.362.6414.513","url":"https://doi.org/10.1126/science.362.6414.513","abstract":"[Excerpt] [...] In mid-October, Harvard University officials disclosed that they have called for the retraction of 31 papers [...] studying the potential of stem cells to repair the heart. And this week, federal officials paused a related clinical study, explaining that the pending retractions ” have raised concerns about the scientific foundations of this trial.” [...] Some critics of his work say studies like the now-halted trial should never have started, given long-standing questions about how – and whether – the cells Anversa studied might repair heart tissue. ” The problem is that if you don't know how something works, then you don't really have a road map of what to address to make it better,” says Deepak Srivastava, a pediatric cardiologist and president of the Gladstone Institutes in San Francisco, California. [...] Further concerns arose this month when Harvard and Brigham and Women's recommended that 31 papers from the Anversa lab be retracted because they ” included falsified and/or fabricated data.” [...] some researchers think the trial should be completed. ” There's plenty of reason to believe that there's still promise,” says cardiologist Christopher Granger of Duke University in Durham, North Carolina. Bolli [...] points to ” overwhelming evidence” from animal studies that c-kit+ cells somehow promote heart tissue growth. ” The controversy [...] does not really change the validity of using c-kit+ cells,” Bolli says. [...]","keywords":"*imported-from-citeulike-INRMM,~INRMM-MiD:c-14652919,epistemology,publication-bias,publish-or-perish,research-management,science-ethics,scientific-community-self-correction,scientific-misconduct","number":"6414","bibtex":"@article{kaiserSuspectScienceLeads2018,\n title = {Suspect Science Leads to Pause in Stem Cell Trial},\n author = {Kaiser, Jocelyn},\n date = {2018-11},\n journaltitle = {Science},\n volume = {362},\n pages = {513},\n issn = {0036-8075},\n doi = {10.1126/science.362.6414.513},\n url = {https://doi.org/10.1126/science.362.6414.513},\n abstract = {[Excerpt] [...] In mid-October, Harvard University officials disclosed that they have called for the retraction of 31 papers [...] studying the potential of stem cells to repair the heart. And this week, federal officials paused a related clinical study, explaining that the pending retractions ” have raised concerns about the scientific foundations of this trial.” [...] Some critics of his work say studies like the now-halted trial should never have started, given long-standing questions about how -- and whether -- the cells Anversa studied might repair heart tissue. ” The problem is that if you don't know how something works, then you don't really have a road map of what to address to make it better,” says Deepak Srivastava, a pediatric cardiologist and president of the Gladstone Institutes in San Francisco, California. [...] Further concerns arose this month when Harvard and Brigham and Women's recommended that 31 papers from the Anversa lab be retracted because they ” included falsified and/or fabricated data.” [...] some researchers think the trial should be completed. ” There's plenty of reason to believe that there's still promise,” says cardiologist Christopher Granger of Duke University in Durham, North Carolina. Bolli [...] points to ” overwhelming evidence” from animal studies that c-kit+ cells somehow promote heart tissue growth. ” The controversy [...] does not really change the validity of using c-kit+ cells,” Bolli says. [...]},\n keywords = {*imported-from-citeulike-INRMM,~INRMM-MiD:c-14652919,epistemology,publication-bias,publish-or-perish,research-management,science-ethics,scientific-community-self-correction,scientific-misconduct},\n number = {6414}\n}\n\n","author_short":["Kaiser, J."],"key":"kaiserSuspectScienceLeads2018","id":"kaiserSuspectScienceLeads2018","bibbaseid":"kaiser-suspectscienceleadstopauseinstemcelltrial","role":"author","urls":{"Paper":"https://doi.org/10.1126/science.362.6414.513"},"keyword":["*imported-from-citeulike-INRMM","~INRMM-MiD:c-14652919","epistemology","publication-bias","publish-or-perish","research-management","science-ethics","scientific-community-self-correction","scientific-misconduct"],"downloads":0},"bibtype":"article","biburl":"https://tmpfiles.org/dl/58794/INRMM.bib","creationDate":"2020-07-02T22:41:10.780Z","downloads":0,"keywords":["*imported-from-citeulike-inrmm","~inrmm-mid:c-14652919","epistemology","publication-bias","publish-or-perish","research-management","science-ethics","scientific-community-self-correction","scientific-misconduct"],"search_terms":["suspect","science","leads","pause","stem","cell","trial","kaiser"],"title":"Suspect Science Leads to Pause in Stem Cell Trial","year":null,"dataSources":["DXuKbcZTirdigFKPF"]}